Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy

Ekenel M., IWAMOTO F. M., BEN-PORAT L. S., PANAGEAS K. S., YAHALOM J., DEANGELIS L. M., ...Daha Fazla

CANCER, cilt.113, sa.5, ss.1025-1031, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 113 Sayı: 5
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1002/cncr.23670
  • Dergi Adı: CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1025-1031
  • İstanbul Üniversitesi Adresli: Hayır

Özet

BACKGROUND. The most effective treatment for a new diagnosis of primary central nervous system lymphoma is high-close methotrexate (MTX)-based chemotherapy followed by whole-brain radiation therapy (WBRT). However, this combined modality treatment carries an increased risk of delayed neurotoxicity. For patients who achieve a complete response (CR) after induction that uses high-dose MTX-based chemotherapy, it is not clear if consolidation treatment is necessary. Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival.